40:I[185,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"SendEmailButton"] 42:I[63625,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"AddToLibraryButton"] 43:I[29721,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"ShareButton"] 44:I[58016,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"ProcessEpisodeButton"] 45:I[45269,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"SignupCTA"] 3a:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2024-10-21T15:12:00.000Z","children":"October 21, 2024"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:18:03"}],false]}] 41:T48f,

Principal Jeff Fineberg, PhD welcomes back returning guest nephrologist Beatrice Goilav, MD, to discuss the program featured at Kidney Week 2024 in San Diego.

Dr. Goilav reflects on what has happened in the field since last year's Kidney Week conference, as well as her hopes for what will be presented at a variety of sessions, including more data in IgA nephropathy, lupus nephritis, and FSGS. She also offers her perspective on the newest advancements with complement inhibitors in glomerular diseases – including approval of FABHALTA® (iptacopan) in IgA nephropathy – as well as recommendations for educational symposia and scientific sessions on the topic. Finally, she and Jeff discuss GLP-1 receptor agonists, and what this class of drug may mean for the management of CKD.

Dr. Goilav hangs out on the social network X. Her handle is @BGoilav, and her DM is open to listeners with follow-on questions.

For more information about Bluestar BioAdvisors, please visit our website.